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RESUMO 
 
 De acordo com a Organização Mundial da Saúde, o Vírus da Imunodeficiência 
Humana, o vírus da Hepatite B e o vírus da Hepatite C são uma das causas mais comuns 
de doença crônica com origem viral em todo o mundo. 
 A enzima Paraoxonase-1 é uma enzima dependente do cálcio associada às 
lipoproteínas de alta densidade, com várias atividades, incluindo paraxaonase, arilesterase 
e lactonase. A capacidade de hidrolisar vários substratos parece dar à enzima propriedades 
antioxidantes e sensibilidade ao estresse oxidativo. 
 Este trabalho faz uma revisão dos estudos mais recentes e relevantes na área e 
tenta demonstrar as interligações e importância da enzima Paraoxonase-1, que pode 
fornecer informações clínicas significativas. 
 Vários estudos apontam para alterações significativas que ocorrem na atividade 
enzimática da Paraxonase-1 em pacientes infetados com vírus da Imunodeficiência 
Humana, vírus da Hepatite B e vírus da Hepatite C. Estas modificações parecem ocorrer 
devido as alterações das atividades da enzima causados pelas infeções no organismo, 
conduzindo a várias perturbações nas vias anti-oxidantes e anti-inflamatórias, que 
parecem envolver a Paraoxonase-1. 
 Sendo as alterações na atividade da Paraoxonase-1 aparentemente motivadas 
por causas malignas, podem ser retiradas informações clínicas úteis através da avaliação 
de tais alterações. A enzima Paraoxonase-1 possivelmente poderá ser usada, com mais 
pesquisas no futuro, como biomarcador para as infeções virais. 
 
 
Palavras-chave: Paraoxonase-1; Vírus da Imunodeficiência Humana; Hepatite B; 
Hepatite C
  ABSTRACT   
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ABSTRACT 
 
 According to the World Health Organization, Human Immunodeficiency Virus, 
Hepatitis B virus and Hepatitis C virus are one of the most common causes of chronic 
viral related disease. 
 The Paraoxonase-1enzyme is a calcium-dependent enzyme associated to high 
density lipoprotein, with various activities, including paraxaonase, arylesterase and 
lactonase. This ability to hydrolase various subtracts seems to give the enzyme anti-
oxidant properties and sensibility to oxidative stress.   
This review cross references the information of most of the recent and available 
studies done in the area and tries to demonstrate the connections and the importance of 
the Paraoxonase-1 enzyme that could provide invaluable clinical information. 
 Several studies conclude that significant alterations occur on the enzymatic 
activity of Paraoxonase-1 in Human Immunodeficiency Virus, Hepatitis B virus and 
Hepatitis C virus infected patients. This modifications seem to occur due to the increased 
levels caused by the infections on the organism, leading to multiple disruption on 
antioxidant and anti-inflammatory pathways that were demonstrated to involve 
Paraoxonase-1. 
 Although Paraoxonase-1 activity alterations seem to be caused by malignant 
causes, positive and useful clinical information might be extracted by measuring such 
alterations. Paraoxonase-1 possibly will be used with more research in future as a 
biomarker for some viral infections.  
 
Key Words: Paraoxonase-1; Human Immunodeficiency Virus; Hepatitis B; Hepatitis C 
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1. INTRODUCTION  
 
Several clinical studies and authors have stated that some viral infections, namely the 
Human Immunodeficiency Virus (HIV), Hepatitis B (HBV) and Hepatitis C (HCV) 
viruses, are somehow related with the paraxonase-1 (PON-1) enzyme that could provide 
invaluable clinical information. 
The purpose of this review is to make an assessment of the most recent data on the 
subject to provide a broader depiction of the field and examine all the available 
information. 
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1.1 – HUMAN IMMUNODEFIECIENCY VIRUS (HIV) INFECTIONS 
 
According to World Health Organization (WHO), over 35 million people have 
globally died from HIV-related causes to date. Almost 1.1million of those deaths were in 
2015 alone (WHO, 2016). According to the report of the Joint United Nations Program 
on HIV and AIDS (UNAIDS) of 2016, there are still 36,7 million people infected around 
the globe (figure 1)  with only 17 million of then been able to access combined 
antiretroviral therapy (cART) (UNAIDS, 2016).  It is considered a major pandemic with 
no cure to date and the only way to keep the disease controlled is throughout the chronic 
use of cART which is expensive and not absent of adverse reactions.  (Carr & Cooper, 
2000; Cost Considerations and Antiretroviral Therapy | Adult and Adolescent ARV 
Guidelines | AIDSinfo, 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The known causing agents of Acquired Immune Deficiency Syndrome (AIDS) are 
HIV-1 (figure 2) and HIV-2. Though they share some similarities (in key proteins like 
Gag or Pol), they differ in almost 50% of their genome. The differences in the viral 
genotype translate in several symptomatic disparities such as the latency period, which is 
increased in the HIV-2 strain, or the increased infection rate observed in HIV-1 strains, 
which remains to date the major culprit of HIV infections all over the world. (Simon, Ho 
& Karim, 2010).
Fig. 1 - Adult HIV prevalence (15-49 years) in 2015 by WHO region. Adapted from Global Health 
Observatory – WHO (2016). 
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In Portugal, HIV infections are caused not only by the HIV-1 variant but by the HIV-
2 genotype due to the geopolitical and historical ties to Guinea-Bissau and Cape Verde, 
were the majority of HIV-2 infections have been recorded (Fernández‐Hidalgo, 
Almirante & Pahissa, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 The worldwide spread of HIV indicates that the virus has one of the most effective 
infection mechanisms, taking advantage of cellular pathways while neutralizing and 
hiding from the immune system. The primary target are CD4+ T lymphocyte cells, which 
are crucible for induction of specific humoral and cell-mediated immune response. In the 
long term, an untreated host will develop opportunist diseases that otherwise would 
remain at bay with an uncompromised immune response and eventually lead to death 
(Sierra, Kupfer & Kaiser, 2005). With access to ART, it is possible to extend the life 
expectancy but with severe complications such as dyslipidemias, atherosclerosis, 
neurodegenerative diseases, to name a few (Depairon et al., 2001; Marsillach, Parra, Coll, 
Joven, & Camps, 2008; Pereira et al., 2009). 
 The HIV replicative cycle (figure 3) is very complex and its duration and outcome 
varies according to the target cell and cell activation (Coffin, Hughes & Varmus, 1997).
Fig. 2 – Diagram of HIV-1 mature virion. MA (matrix protein); CA (capsid protein); NC 
(nucleocapsid protein); RT (reverse transcriptase); RNA (ribonucleic acid); gp120 and gp41 
(glycoprotein receptors). Adapted from Sierra et al. (2005). 
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Over the years several strategies were established to decrease the viral load hoping 
to increase the quality of life of infected patients and even develop a possible cure. Several 
antiretroviral drugs have been created that exploited numerous key stages in the 
replicative cycle of the virus, such as fusion inhibitors, entry inhibitors, reverse 
transcriptase inhibitors (nucleotide based and non-nucleotide based), protease inhibitors 
and integrase inhibitors (table 1) (FDA, 2016).
Fig. 3 – HIV-1 replicative cycle and main antiretroviral therapeutical targets. Once a mature virion 
attaches itself to the CD4 membrane receptor of the lymphocyte T cell, it begins a fusion process in with 
it releases all the viral machinery into the cell, including the viral RNA and reverse transcriptase. Then 
it starts to reverse transcript the RNA into the pre-integration complex, which is incorporated in the cell’s 
DNA via integrase. Once integrated in the nuclear DNA, it begins the transcription and translation 
process, taking advantage of the cells own machinery. Once all the viral component are fully formed, 
they start to assembly and release themselves from the cell creating a new immature virion. For a time 
this virion undergoes a maturation process by the viral protease to produce all the mature viral particles. 
Adapted from Sierra et al. (2005). 
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Drug Class Generic Name 
Nucleos(t)ide Reverse Transcriptase Inhibitors 
(NRTI’s) 
 
Abacavir 
Didanosine 
Emtricitabine 
Lamivudine 
Stavudine 
Tenofovir  
Zidovudine 
Non-Nucleoside Reverse Transcriptase Inhibitors 
(NNRTI’s) 
Efavirenz 
Etravirine 
Nevirapine 
Rilpivirine 
Protease Inhibitors (PI’s) 
Atazanavir 
Darunavir 
Fosamprenavir 
Indinavir 
Nelfinavir 
Ritonavir 
Saquinavir 
Tipranavir 
Fusion Inhibitors (FI’s) Enfuvirtide 
Entry Inhibitors (EI’s) Maraviroc 
Integrase Inhibitors (II’s) 
Dolutegravir 
Elvitegravir 
Raltegravir 
  Adapted from FDA (2016). 
 
HIV infections are prone to cause lipid and acute phase protein (APP) alterations 
(Treitinger et al., 2001), especially during the initial stages of infection. Some lipid 
modifications might be related to the host’s reaction to infection intermediated by 
cytokines, seen as an increase in serum Tumor Necrosis Factor (TNF), interleukins and 
decrease in High Density Lipoprotein (HDL) cholesterol (Feingold & Grunfeld, 1992), 
which can be linked to viral replication and consequent cholesterol membrane 
metabolism (Ono & Freed, 2001; Rose et al., 2008). The acute phase response has been 
shown to be correlated to the increase in plasma triglyceride concentrations and the 
increased turn-over and loss of protein mass (Treitinger et al., 2001).  
 
 
 
Table 1 - Antiretroviral drugs used against HIV. 
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1.2 - HEPATITIS B INFECTIONS 
 
Hepatitis B is also a disease caused by a viral infection. The causing agent is the 
Hepatitis B Virus (HBV) which is a small, enveloped DNA virus that belongs to the 
Hepadnaviridae family. It targets liver cells and can cause acute or chronic liver disease. 
According to the WHO, in 2016, more than 240 million people were chronically infected 
with HBV, with 686,000 people dying every year from complications related to the 
disease (WHO, 2016a). This infection can be easily prevented by vaccination, however 
high costs and lack of awareness of HBV infection risks hamper the successful outcome 
of immunization. Also, the high prevalence in some regions (e.g. Asia) is due to vertical 
transmission of HBV virus, from chronically infected mothers (Grimm, Thimme & Blum 
2011). 
HBV is a small, enveloped DNA virus (figure 4). There are currently eight known 
different genotypes (A-H), being the A and D the most common in Europe. The virus 
itself does not seem to be cytopathic. The cytotoxicity in HBV infection comes from 
immune mediated responses (Grimm et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
Currently, there are seven drugs approved by both the Food and Drug Administration 
(FDA) and European Medicines Agency (EMA) for hepatitis B infections (figure 5).
 
Fig. 4 – Diagram of HBV virion. Envelope proteins, S, M, L, with their S, preS2 and preS1 domains. 
The HBV genome (HBV RC DNA), in the capsid, is a partly double stranded, incomplete circle, with 
the polymerase (pol) attached to the “minus” strand. Adapted from Locarnini (2004). 
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The conventional interferon-alfa (IFN-α), the PEGylated interferon-alfa (pegIFN-α) and 
the nucleotide/nucleoside analogues (NUC’s), such as adefovir, entecavir, telbivudine 
and tenofovir and lamivudine, also both used in HIV infections (EASL, 2012; Stein & 
Loomba, 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The aims of cART are preventing disease progression to cirrhosis, end-stage liver 
disease or death and to improve the quality of life of chronically HBV-infected patients 
(Wang, 2012).
Fig. 5 – HBV replicative cycle and targets for antiviral therapy. HBV uses reverse 
transcription despite not being a retrovirus. In its replication process the virus gains entry into the 
cell by binding to the sodium taurocholate co-transporting polypeptide receptor on the surface 
is endocytosed. Because the virus multiplies via RNA made by a host enzyme, the viral genomic 
DNA has to be transferred to the cell nucleus by host proteins called chaperones. The partially 
double stranded viral DNA is then made fully double stranded by viral polymerase and transformed 
into covalently closed circular DNA (cccDNA). This cccDNA serves as a template for transcription 
of four viral mRNAs by host RNA polymerase. The largest mRNA, (which is longer than the viral 
genome), is used to make the new copies of the genome and to make the capsid core protein and the 
viral DNA polymerase. These four viral transcripts undergo additional processing and go on to form 
progeny virions that are released from the cell or returned to the nucleus and re-cycled to produce 
even more copies. Adapted from Grimm, Thimme & Blum (2011) and  Stein & Loomba (2009). 
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More than 95% of patients with acute HBV infection recover spontaneously and 
without the necessity for ART (Tassopoulos et al., 1987). However, patients with 
fulminant or severe hepatitis must be evaluated for liver transplantation (Castaldo & 
Chari, 2006).  
Occasionally, the division amongst true acute hepatitis B and reactivation of HBV is 
problematic and often requires a liver biopsy. Although nucleotide analogues therapy is 
first line treatment in each case (Tillmann et al., 2006; Garg et al., 2011;).  
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1.3 – HEPATITIS C INFECTION 
 
Hepatitis C is also a disease caused by a RNA virus (HCV) (from the Flaviridae 
family), with more than 86% chance of developing chronic infection. By the WHO 
assessments, it is estimated to affect at least 150 million people chronically worldwide, a 
significant proportion prone to develop complications like cirrhosis or liver cancer 
(WHO, 2016b). Although drugs can cure approximately 90% of people, the access to 
diagnosis and treatment is highly ineffective. This is due mainly to the high cost of 
treatment (WHO, 2016b). 
Hepatitis C can be found worldwide but the most affected regions are Africa and 
Central Asia (WHO, 2016b). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 – Diagram of HCV virion. HCV adopts an icosahedral scaffold; glycoproteins E1 and E2 are 
attached to the lipid envelope. Inside the envelope is the nucleocapsid or core, forming an internal 
icosahedral viral coat that encapsulates the viral genomic positive-strand RNA. Adapted from Chevaliez 
& Pawlotsky (2006). 
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The diagnosis of hepatitis C is divided in two steps, the first constitutes the screening 
for anti-HCV antibodies with a serological test. The second part is a confirmation test 
which screens for RNA. This is because some people are able to fight the initial infection 
successfully and no longer have the virus but still test positive for the anti-bodies of HCV 
(WHO, 2016b). 
Nowadays, the available ART options are very effective (figure 7). However, as above 
mentioned, they can be extremely expensive. To date, there are no vaccines available has 
for preventing HCV infection (“Hepatitis B and C - Hepatitis B and C Treatments,” 2016.; 
“WHO | Hepatitis C,” 2016).  
HBC and HCV are both prone to cause chronic liver disease and increase the 
occurrence of reactive oxygen species and hepatic lipid peroxidation. This causes an 
accumulated oxidative stress that leads to liver cell apoptosis (Zeisel, Crouchet, Baumert 
& Schuster, 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7 – Schematic representation of the HCV replicative cycle and targets for antiviral 
therapy. HCV interacts with the basolateral membrane of hepatocytes, resulting in viral entry into 
the host cell. The virus is internalized via endocytosis and translation of the HCV RNA occurs in 
the cytoplasm following viral fusion and uncoating. Viral replication takes place within the 
cytoplasm in perinuclear endoplasmic reticulum (ER)-derived membranes called the “membranous 
web”. Progeny virions are assembled on cytosolic lipid droplets and subsequently transported along 
the secretory pathway and maturated in the Golgi before their release through microtubular transport 
and endocytic recycling compartment. Targets for antiviral therapy are highlighted in red. Adapted 
from Zeisel et al. (2015) 
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1.4 – BIOMARKERS FOR VIRAL DISEASE 
 
 A biomarker is a quantifiable biological or biochemical variable which 
indicates, when measured objectively, the functioning of biological processes, pathogenic 
or a pharmacological response to a given therapy (Strimbu & Tavel, 2010). It is normally 
found in blood, urine, tissue biopsy, saliva or other biological samples. Continued 
research into a number of urinary, serologic and genetic biomarkers, will guide clinicians 
with diagnosis, prognosis, and treatment. (Vasan, 2006; Downes & Shah, 2012). Ideally, 
the means of analysis of a clinical biomarker of interest must meet certain requirements 
such as high reproducibility, precision and specificity (Laborde et al., 2012). 
 In viral infections such as HIV, HBV or HCV infections, early diagnosis is 
critical to improve not only the therapeutic outcomes, but also the survival rate and the 
prognosis. PON-1 enzyme appears to be sensitive in early stages of some viral infections 
and to the course of their progression due to a close association of the enzyme with 
oxidative stress (Rose et al., 2006; Gangadharan, Antrobus, Dwek & Zitzmann, 2007; 
Marsillach, Parra, Coll, Joven & Camps, 2008; Ali, Shehata, Ali-Labib & Zahra, 2009; 
Downes & Shah, 2012). If a relation can be establish, a new biomarker to better evaluate 
patients and the progression of disease may be developed. 
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1.5 – PARAOXONASE-1 
 
Paraoxonases (PON´s) are a family of enzymes, called PON-1, PON-2 and PON-3. 
Their genes are located in humans at the chromosome 7q21-22 (Kulka, 2016; Primo-
Parmo, Sorenson, Teiber & La Du, 1996). 
PON-1 was first described by Abraham Mazur, in 1946,  who reported the existence 
of an enzyme capable of hydrolyzing organophosphates in animal tissues (Mazur, 1946). 
This eventually led to the discovery of PON-1 in the early 1950’s (Aldridge, 1953). 
Described as a calcium dependent serum HDL-associated serum aryldialkylphosphatase 
(Aldridge, 1953), the structure of PON-1 (figure 8) consists of a six-bladed β-propeller, 
each blade consisting of four β-sheets. In the active center of the PON-1 enzyme there is 
a tunnel containing two calcium atoms that is crucial for structural stability and catalytic 
activity. The enzyme also has an anchoring portion for the High Density Lipoprotein 
(HDL) particle that is located at the top of the propeller which has three α-helices (figure 
9)  (Harel et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8 – Schematic representation of overall structure of PON-1. a) View of the six-bladed β-
propeller from above. The top of the propeller is, by convention, the face carrying the loops connecting 
the outer β-strand of each blade (strand D) with the inner strand (A) of the next blade. Shown are the N 
and C termini, and the calcium atoms in the central tunnel of the propeller (Ca1, green; Ca2, red); b) A 
side view of propeller, including the three helices at the top of the propeller (H1–H3). N-terminal 
residues 1–15 and a surface loop connecting strands 1B and 1C (residues 72–79) are not visible in the 
structure. Adapted from Harel et al. (2004). 
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The enzyme was named after studying its first known subtract, paraoxon, an active 
metabolite of the organophosphate parathion (Lessire et al., 1996; van Himbergen, van 
Tits, Roest & Stalenhoef, 2006). The ability of PON1 to hydrolyze paraoxon has been 
largely employed over the years for  quantifying the activity of different enzyme variants 
and their tissue concentrations (figure 10) (Shih et al., 1998; Camps, Marsillach & Joven, 
2009). Over the years it became clear that the activity of PON-1 was highly variable 
according to the genetic background of the individual, making possible to associate 
certain alleles with the activity of the enzyme. It was also showed that the presence of 
low-activity alleles varied considerably between each ethical group, with elevated 
frequency being perceived in Caucasian populations (Eckerson, Wyte & La Du, 1983). 
 
 
 
Fig. 9 – Schematic representation of PON-1 anchored to HDL. Adapted from Harel et al. (2004). 
 
Fig. 10 – Hydrolysis reaction of paraoxon by PON-1. DEP – dietil-fosfate; PNP – p-nitrofenol. 
Adapted from Chambers (2008) 
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PON-1 has demonstrated a strong lactonase activity for homocysteine-thiolactone and 
other xenobiotic lactones (Jakubowski, 2000; Ng et al., 2005). Being evolved in the 
homocysteine metabolism via homocysteine-thiolactone (figure 11), the impact of the 
study of PON-1 increases, specially due to its possible role in the prevention of 
cardiovascular diseases (mainly atherosclerosis) (Shih et al., 1998) and involvement in 
Alzheimer’s disease (Jakubowski, 1997; Cervellati et al., 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11 – Lactonase activity of PON-1 in the homocysteine methabolism. Homocysteine (Hcy) is 
maintained at very low levels in serum due to the methionine cycle, which leads to a rapid methyl 
transfer reaction using the following enzyme substrates: methionine (Met), S-adenosyl-methionine (S-
Adenosyl-Met), and S-adenosyl-homocysteine (S-Adenosyl-Hcy). The methionine cycle is controlled 
by methionine synthase (MS), betaine-Hcy methyltransferase (BHMT), methionine adenosyltransferase 
(MAT), methyltransferase (MT), and S-Adenosyl-Hcy hydrolase (SAHH). Met and Hcy are also 
metabolized by methionyl-tRNA synthase (MetRS) to become Met- tRNA and Hcy-thiolactone (HT). 
Under normal conditions, Hcy-thiolactone is rapidly converted to Hcy by Hcy-thiolactonase (HTase), 
in this case PON-1. HT reacts spontaneously with protein ε-lysine residues, leading to formation of N-
Hcy-protein. Alternatively, Hcy can enter the transsulfuration pathway. It is then converted to 
cystathionine (Cyst) by cystathionine β - synthase (CBS), which is further converted to cysteine (Cys) 
by cystathio- nine γ-lyase (CSE). The transsulfuration pathway ends with sulfate. Adapted from Usuki 
(2012) 
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According to Aviram et al., (1998), PON-1 might have two different active sites that 
give it asterolytic and hydroxyperoxide activities - the first one metabolizes substrates 
such as esterified lipids, while the lather is involved in the reduction of hydroperoxides. 
It has been suggested that both catalytic activities may act in sequence, as seen with p-
nithophenol 13-hydroperoxylinoleate when used as PON-1 subtract. The reduction 
mechanism paralleled hydrolysis, indicating an esterolytic activity requirement before the 
esterified fatty acid hydroperoxide is reduced (Karabina, Lehner, Frank, Parthasarathy & 
Santanam, 2005).  
Human PON-1 is thought to be mainly synthetized and secreted by the liver. In fact, 
Northern-blot analysis of hepatic tissue samples presented only positive results for PON-
1 mRNA (Hassett et al., 1991). However, recent evidences suggested that other tissues 
such as lungs, brain, pancreas, small-intestine and kidney have the same capacity; the 
presence of PON-1 mRNA in such tissues was detected, using reverse transcriptase 
polymerase chain reaction technique (RT-PCR) (Eckerson et al., 1983). Nevertheless, the 
liver is, the most likely source of PON-1 due to the high PON-1 gene expression; besides, 
it is here that HDL is synthesized and secreted into the circulation.  
Human HDLs particles form a heterogeneous group of lipoproteins, classified 
according to their increasing size and lipid and protein composition: HDL3c, HDL3b, 
HDL3a, HDL2a, HDL2b (Rosenson et al., 2011). In bovine serum, 85% of the total PON-1 
activity has been associated with HDL fractions. Less than 5% of the total PON-1 activity 
was identified in very low density lipoproteins (VLDL) and low density lipoprotein 
(LDL) (Miyamoto, Takahashi, Oohashi, Sato, & Oikawa, 2005). 
There is no consensus about the major role of PON-1 in the human organism. The 
first hypothesis was proposed by Mackness, Arrol & Durrington (1991). This research 
work highlighted the safeguards against copper-induced LDL oxidation provided by HDL 
and PON-1. It was observed that PON-1 prevented lipoperoxide generation during the 
process of LDL oxidation, which indicated that this enzyme might be involved in a 
protective function of HDL. Of notice is that a PON-1 free sulfhydryl group in cysteine 
284 was shown to be essential for the enzyme’s activity against lipid peroxides but not 
for its activity against paraoxon or other xenobiotics. This suggests that the mechanisms 
of hydrolysis are somewhat different (Aviram et al., 1998). 
PON-1 is also regarded as a negative acute phase protein and its concentration seams 
to decrease during inflammatory conditions. In humans and rabbits, during acute phase 
response, apolipoprotein A-I (ApoA-1) concentration and PON-1 activity were 
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simultaneously depleted (Lenten et al., 1995). It appears that under inflammatory 
conditions, a displacement of the Apo A-1 by the positive acute phase proteins (APPs) 
serum amyloid A (SAA) in HDL might occur, thus leading to a decrease in PON-1 
activity. However, in mice with acute infection a decrease in PON-1 and platelet 
activating factor acetyl-hydrolase (PAF-AH) activities was concomitant with unchanged 
Apo A-1 levels (Lenten et al., 2001). Acute phase response induced by endotoxin, 
lipopolysaccharide (LPS), caused a decrease in PON-1 serum activity (over 60%) within 
48 hours in Syrian Hamsters and initiated a rapid decrease in PON-1 mRNA 
concentrations, persisting for at least 48 hours, in hamster hepatic cell cultures. Moreover, 
it was observed that mediators such as TNF and IL-1 diminished PON-1 activity in a 
similar manner (Feingold, Memon, Moser & Grunfeld, 1998).  
The enzyme PON-1 shows a similar behavior to other APPs during the inflammatory 
process. PON-1 negative acute phase response changes with the elevation of APP 
positive, when measured in severe conditions in human sepsis and animal parasitic 
infections. People in critical states during infection had decreased PON-1 activity and a 
noteworthy negative correlation with C reactive protein (CRP) (Novak et al., 2010), 
which is a well-studied positive acute phase protein (Jain, Gautam, & Naseem, 2011).  
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2. DEVELOPMENT 
 
2.1 – PON-1 AND HIV INFECTIONS 
 
2.1.1 – PON-1 ENZYME AND HDL  
 
As mentioned before PON-1 is an esterase/lactonase enzyme, present in HDL, with a 
broad spectrum of substrates. Yet, its physiological function is not completely 
understood. However, a considerable amount of evidence suggests that, among other 
roles, PON-1 may hydrolyze oxidized lipid peroxides from LDL and HDL and, thus, 
possess antioxidant and anti-inflammatory properties (Parra et al., 2007). 
Several studies have shown significant alterations on the enzymatic activity of PON-
1 in HIV infected patients. Severe dyslipidemias and low levels of HDL (Riddler et al., 
2007; Stein et al., 2008) cause long-term infected HIV patients to develop increased risk 
of cardiovascular diseases (Lang et al., 2010).  
Low levels of HDL cholesterol is widely prevalent in Western countries, and is an 
independently predictive risk of cardiovascular disease, even in individuals with low 
concentrations of LDL. However, low concentrations of HDL are frequently concomitant 
with increased concentrations of small, cholesterol-depleted LDL particles and increased 
concentrations of cholesterol enriched triglyceride remnants. Thus, the cardiovascular 
risk associated with low HDL values is difficult to distinct from that of other associated 
lipoprotein abnormalities (Assmann, Schulte, Von Eckardstein & Huang, 1996; Otvos, 
Jeyarajah & Cromwell, 2002). 
The decrease of lipid transfer to HDL, including free cholesterol, triglycerides and 
phospholipids, seems to severely disturb the protective antioxidant role provided by PON-
1 HDL, disrupting the protection provided against the peroxidation of LDL and also in 
inflammatory processes, mainly the protection against free-radicals generated by 
homocysteine-thiolactone (HCTL) (Olszewski & McCully, 1993; Jakubowski & 
Gtowacki, 2011). 
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2.1.2 – PON-1 IN HIV INFECTED PATIENTS 
 
Viral replication and some clinical manifestations of HIV infection involve an 
imbalance in the reduction–oxidation status and free radical production (Schwarz, 1996). 
It is likely that the HIV-induced oxidized environment could result in an increased 
binding of free radicals to PON-1, resulting in a less active enzyme in circulation; in 
agreement to the reports of oxidized lipids reacting with a free (–SH) group at PON’s 
cysteine-284 site leading to inactivation of the enzyme. Another reason for this decrease 
could be the lower concentrations of HDL cholesterol and Apo A-1 (Aviram et al., 1999). 
HIV infected patients frequently develop long-term pro-atherogenic metabolic 
modifications. These problems may be explained by the infection itself or by secondary 
effects of the ART, mainly protease inhibitors (Périard et al., 1999). These findings gained 
additional clinical relevance since the introduction of effective therapeutic measures, 
which have gradually changed HIV infections from a life threatening to a chronic disease. 
Furthermore, the combination of classical cardiovascular risk factors with some genetic 
polymorphisms appears to predispose these individuals to a higher risk of premature 
arteriosclerosis (Alonso-Villaverde et al., 2005; Coll et al., 2005; Coll et al., 2006). There 
are changes in lipoprotein metabolism in the course of HIV infection, including increased 
lipid peroxidation, hypocholesterolemia, hypertriglyceridemia and low HDL 
concentration (Rose et al., 2006). Also, patients with higher HDL concentrations appear 
to have a better disease course than patients with lower HDL concentrations (Alonso-
Villaverde et al., 2003). 
When PON-1´s activity is compared between HIV infected patients and healthy 
subjects, it is possible to conclude that the activity is decreased in HIV infected patients 
(44.3 nmol.min-1.mL-1 ± 38.6 vs 71.8 nmol.min-1.mL-1  ± 37.4 ; p=0,001) (Daminelli et 
al., 2008). Regarding to HDL levels, it is dependent on the cART and the viral load of the 
patient (table 2) (Siegel et al., 2015). It has also been observed that the ratio of PON-1 
activity/HDL is increased in treated patients with cART containing the non-nucleoside 
reverse transcriptase inhibitor Efavirenz (table 3) (Pereira et al., 2009). The enzymatic 
activity of PON-1 and the HDL serum levels become a potential marker that is worth 
exploring in order to evaluate the possible risk of cardiovascular diseases in HIV-infected 
patients and to assess the progression of the disease (Marsillach et al., 2008). 
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 Controls HIV+ N ART HIV+ PI VL+ HIV+ PI VL- HIV+ NNRTI 
HDL (mg/dl) 56  45.1 54.4 56.1 54.1 
ART – antiretroviral therapy; VL ± - viral load above or below detection limit (20 copies/ml); adapted from 
Siegel et al. (2015). 
 
 
Parameters Untreated Treated (Efavirenz) 
HDL (mg/dl) 48 46 
PON-1 paraxaonase activity (U/L) 58,8 77,35 
PON-1 activity /HDL ratio 1,3 1,88 
Adapted from Pereira et al. (2009). 
 The evidence provided by this study is reinforced in a work presented by Marinho 
et al. (2016) in which is demonstrated once again that PON-1 activity increases when 
using cART containing a different NNRTI, Nevirapine (Marinho et al., 2016). 
In a study published by Daminelli et al. (2008) (table 4), the HIV+ group of 
patients showed that the LDL cholesterol and triglyceride levels in plasma are decreased 
than those of the control group, while HDL levels were identical. HIV+ patients 
frequently show reduced LDL, but triglycerides are generally described as increased 
(Treitinger et al., 2001), in contrast with the results of this study. However, increased 
triglyceride concentration leaded to a HDL cholesterol decrease, and the fact that 
triglycerides were not increased in the HIV+ group ultimately facilitated the analysis of 
HDL. According to Daminelli et al. (2008), the three subgroups of HIV-infected patients 
did not differ among them in respect to LDL. Regarding HDL, however, its levels were 
higher in the subgroup treated with NRTI plus NNRTI combined therapy, when compared 
with the subgroup treated with NRTI plus PI therapy, with non-treated HIV+ patients or 
with the values of the control group.  The diminution of PON-1 activity in HIV-infected 
patients confirms the findings of Parra et al. (2007), in both treated and non-treated 
patients.  
Table 2 - Clinical study comparing HDL levels in human serum between healthy subjects, infected 
HIV patients with or without ART and between the most used ART’s.   
Table 3 - Comparison between biochemical variables between Caucasian HIV-infected patients 
without treatment and HIV-infected patients on antiretroviral therapy containing Efavirenz. 
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Adapted from Daminelli et al. (2008) 
 
In fact,  Parra et al. (2007)  found a reduction in PON-1 activity with an increase 
in its concentration in HIV infected patients, which could be explained by the addition of 
a higher quantity of free radicals to PON-1, by lower serum concentrations of HDL and 
Apo A-1 and by changes in the liver that would influence the serum concentration of 
PON-1 (table 5).  
 
 
 
 
 
 
 
 
 
Reprinted from Parra et al. (2007) 
 
The results from this study indicated that the co-infection with HCV was 
associated with a significantly lower PON-1 activity and decreased amount of oxidized 
LDL. There were no significant differences regarding PON-1, HDL or Apo A-1 
concentrations. Patients with an active viral replication had higher PON-1 concentrations 
and lower HDL cholesterol levels. It was not found any significant difference in PON-1 
activity between these two groups. The three groups, stratified according to the CD4+ T 
Parameters Controls Untreated 
NRTI + 
NNRTI 
NRTI + PI 
HDL (mg/dl) 41 39 53 38 
PON-1 (paraoxonase) (nmol.min-1.ml-1) 72 46 55 34 
LDL (mg/dl) 127 100 106 97 
Triglycerides (mg/dl) 116 98 103 98 
Table 4 - Comparison between biochemical variables in healthy subjects and treated and non-
treated HIV+ patients. 
Table 5 - Variations of PON-1 activity and concentration, HDL cholesterol ApoA-I and oxidized 
LDL with gender, presence of HCV co-infection, lipodystrophy, CD4+ cell count and viral load. 
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lymphocyte count, did not present any significant differences in PON-1 status, HDL-
cholesterol, Apo A-1 or oxidized LDL levels. The presence of lipodystrophy was 
associated with lower HDL-cholesterol concentrations and higher oxidized LDL levels. 
CD4+ T and CD8+ T lymphocyte cell counts showed weak negative correlations with 
PON-1 concentration (Parra et al., 2007). 
 In regards to ethnicity, specifically between Caucasian and Black patients, Pereira 
et al. (2009) demonstrated that it is also important to take into account the genetic 
variability specifically those of individuals of different ethnicities, when evaluating PON-
1 activity. Other studies do not take the genetic variability into account (Alonso-
Villaverde et al., 2003; Maselli et al., 2014; Parra et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Only a few studies have been published to date regarding  the association between 
HIV infection and PON levels, and these have produced diverse results (Parra et al., 2007; 
Daminelli et al., 2008; Pereira et al., 2009). Daminelli et al. (2008) verified a significant 
decreased activity of PON-1 in HIV+ patients compared to healthy controls; ART 
Fig. 12 - PON-1 activity HIV in infected individuals. PON-1 activity was lower in untreated [58.80 
U.L-1 (51.36, 66.23); n = 18] than in treated [77.35 U.L-1 (65.66, 89.04); n = 18]; Caucasian patients 
and both were lower than Black patients despite treat- ment (*P < 0.05, **P < 0.01 and ***P < 0.001, 
one-way ANOVA plus Bonfer-roni’s multiple comparison test); No treatment       ; treated with 
Efavirenz (?)  . Adapted from Pereira et al. (2009). 
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treatment did not reverse this deficiency. Parra et al. (2007) also found decreased PON-1 
activity but also identified an increased PON-1 concentration in HIV+ patients compared 
to heathy controls.  
Siegel et al. (2015) measured both the activity and concentration of PON-1 in 
HDL particles, and found decreased levels of both. In light of the findings by Parra et al. 
(2007) it was proposed that a defect in incorporation of PON-1 into HDL, rather than low 
PON-1 abundance in these patients, was responsible for the low PON-1 concentrations. 
PON-1 activity measured in isolated HDL inversely correlates with age (Çakatay, Kayali, 
& Uzun, 2008) on which, given that the average age control group in Siegel et al. (2015) 
was younger than the one in the HIV+ patients, could contribute to lower the PON-1 
activity. On the other hand, Maselli et al. (2014) stated that there was no correlation 
between PON-1 activity and serum levels of HDL, possibly because the clinical data of 
the study does not provide significant statistical differences between groups.
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2.1.3 – PON-1 ACTIVITY, CD4+ AND CD8+ T-CELLS IN HIV INFECTED 
PATIENTS 
 
The Maselli et al. (2014) work showed  lower serum PON-1 activity in HIV+ patients 
with no ART (table 6). PON-1 activity showed a significant positive correlation with the 
number of CD4+ T-cells in HIV+ patients with no ART, suggesting that the immune status 
may directly affect the activity of PON-1. Other studies have shown that enzyme levels 
are reduced in HIV+ patients with no ART who have a reduced number of CD4+ T-cells 
(Le Moing et al., 2007). Thus, it might be proposed the existence of a relationship between 
the number of CD4+ T-cells and PON-1 activity, which would be directly related to a 
good outcome in a HIV infection. It remains uncertain whether the replication of the HIV 
virus itself would be related to PON-1. According to Maselli et al. (2014)  the study 
established the factor that likely determines the reduction of PON-1 activity is the 
suppression of the immune system by HIV (Maselli et al. 2014). 
 
Adapted from Maselli et al. (2014) 
According to Pereira et al., (2009) there is also a possible relation between PON-1 
activity and CD4 cell count, corroborated by other studies (Parra et al., 2007; Parra et al., 
2010). It should be taken in consideration that in early studies there was no differentiation 
between HIV patients with and without co-infection by Hepatitis C virus, that can largely 
affect the outcomes on PON-1 activity, since this enzyme is mainly synthetized in the 
liver and a marker of hepatic function (Ferré et al., 2006). 
Parameters Controls Untreated Efavirenz/Nevirapine Lopinavir/Ritonavir 
CD4+ T-cells (cells/mm3) ND 404 483 486 
CD8+ T-cells (cells/mm3) ND 955 859 952 
CD4:CD8 ratio ND 0.4 0.5 0.5 
HIV-1 RNA (copies/ml) - 89.266 14.121 16.301 
PON-1 paraoxonase activity 
(U/L) 
117 81 109 106 
Table 6 - Comparison between PON-1 activity and HIV markers of infection. 
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2.1.4 THE ANTIOXIDANT AND ANTI-INFLAMATORY ROLE OF PON-1 IN  HIV 
INFECTED PATIENTS  
 
In the work publish by Dias et al. (2014), the lactonase activity was examined in a 
cohort of HIV infected patients,  regardless of combined ART in use. Untreated patients 
and patients who had received continuous ART for more than one month were included. 
The study suggests that lower lactonase activity is associated with uncontrolled HIV 
infection, particularly with non-suppressed viremia, despite of ART. The data points for 
lactonase activity to have a role in HIV-infection, probably reflecting an increased 
formation of HCTL species. The study also proposes that a better understanding of the 
lactonase activity and its role in HCTL pathophysiology might identify new therapeutic 
targets in HIV infected patients (Dias et al., 2014).
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2.1.5 PON-1 HAS A BIOMARKER FOR HIV INFECTION  
 
According to Parra et al. (2007), serum PON-1 concentrations showed a strong 
correlation with β-2-microglobulin concentration [B=75.19 (50.32–100.06); p<0.001]. 
Given that β-2-microglobulin is a known effective marker of infection by HIV (Savès et 
al., 2001), this association might be worth exploring and could lead into new ways to 
better monitor the infection at multiple levels. 
Maselli et al. (2014) demonstrated that the enzymatic activity of PON-1 is correlated 
with CD4+ T-cell count in patients not receiving ART. The demonstration that PON-1 
activity was reduced in untreated patients, but not in individuals receiving ART, 
suggested that the activity of PON-1 is associated with the immune status of HIV-1 
infected individuals, making the enzymatic activity a good candidate for an alternative 
biomarker (Maselli et al., 2014). 
By quantifying the activity of PON-1 in HIV infected patients and being able to 
gradually establish correlations with treatment outcomes and the progression of the 
disease, it make it possible to progressively develop a new, efficient monitorization 
biomarker that is easy to quantify and evaluate (Parra et al., 2007; Maselli et al., 2014; 
Kulka, 2016). 
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2.2 – PON-1 AND VIRAL HEPATITIS (HBV AND HCV) 
 
2.2.1 – PON-1 ACTIVITY AS A BIOMARKER FOR LIVER DISEASE 
 
Chronic hepatitis is included in a group of liver disorders where the hepatic 
inflammation and necrosis lasts for more than six months. The severity of the disease 
might vary from minor forms, in which the progression is very slow and might go 
undetected for an extended period of time, to more serious forms which are linked with 
liver parenchymal scarring and structural disorders that progress to cirrhosis (Fauci, 
Kasper, Longo, Hauser & Jameson, 2015). 
In chronic liver diseases of slow progression the traditional liver function tests often 
remain unaltered, until more severe forms of hepatic disorder becomes apparent.  
In order to diagnose such slow progressive liver diseases before reaching advanced 
states such as hepatocellular necrosis and fibrosis, aside the outdated biochemical tests, 
alternative parameters become necessary to evaluate liver damage (Fauci, Kasper, Longo, 
Hauser & Jameson, 2015). 
Currently histopathological analysis of liver biopsy samples are considered the best 
method to accurately diagnose liver disease. However, liver biopsy is an invasive 
technique with inevitable complications (Sanai & Keeffe, 2010). Once more, the need for 
a trustworthy and accurate diagnostic tool that does not require invasive and painful 
procedures emerges. In this regard, it would be convenient to find a hepatic biomarker, 
preferably one that can be  easily and quickly assessed (Gangadharan, Antrobus, Dwek 
& Zitzmann, 2007; Marsillach et al., 2008). 
The pathogenesis of numerous liver diseases are often associated with oxidative stress 
(Tanikawa & Torimura, 2006). The oxidative stress is strongly linked to the progression 
of alcoholic liver disease, non-alcoholic steatohepatitis and hepatitis B and C virus 
infection, which can lead to the development of acute hepatitis, chronic hepatitis, 
hepatocellular carcinomas and liver cirrhosis (Gil, Pla, Gonzalvo, Hernández & 
Villanueva, 1993).  
The PON-1 enzyme is able to protect against oxidative stress by inhibiting lipid 
peroxidation (Aviram et al., 1998; Mackness, Durrington & Mackness, 2004). This raises 
the hypothesis that an association between oxidative stress and PON-1 activity in liver 
disease might exist (Mackness & Durrington, 1995).  
Some of the studies performed in this context have detected a substantial reduction of 
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serum PON-1 activity in patients with chronic hepatitis (Ferré et al., 2002; Ferré et al., 
2005; Kilic, Aydin, Kilic, Erman, Aydin & Celik, 2005).  
Recently, Pyati (2015) showed that serum basal PON-1 activity is considerably 
reduced (p < 0.001) in patients with chronic hepatitis when compared to healthy controls. 
These findings are in agreement with the results from the studies reported by  Başkol, 
Başkol, Deniz, Ozbakir, & Yücesoy, (2005); N. Ferré et al., (2002), (2005); Kilic, Aydin, 
Kilic, Erman, Aydin, Suleyman, et al., (2005) and Ali, Shehata, Ali-Labib, & Zahra, 
(2009). 
According to Pyati (2015) (table 6), the activity of  PON-1 is positively correlated 
with total serum protein levels and albumin levels, and are negatively correlated with 
serum bilirubin, alanine aminotransferase (ALT), and alkaline phosphate (ALP), with a 
great statistical significance (p< 0.001). No such correlation has been demonstrated 
between standard liver function tests and basal PON-1 activity in healthy controls. These 
results are consistent with previous works (Ferré et al., 2002;  Ferré et al., 2005; Kilic, 
Aydin, Kilic, Erman, Aydin, Suleyman, et al., 2005; Başkol et al., 2005; Ali, Shehata, 
Ali-Labib, & Zahra, 2009). 
 
Adapted from Pyati (2015) 
 
According to Pyati (2015), basal PON-1 activity seems to be a better marker for 
diagnosis of chronic hepatitis than total protein, albumin and ALP with a sensitivity of 
68% and specificity of 100%. It also demonstrated a positive predictive value of 100% 
Parameters Controls Chronic Hepatitis p-value 
Age 45.6 ± 11.8 41.8 ± 9.8 0.080 
Total Bilirubin (%) 0.74 ± 0.14  4.05 ± 1.74  < 0.001 
Total Protein (%) 6.83 ± 0.72  6.2 ± 0.34  < 0.001 
Albumin (g/dl) 3.72 ± 0.55 
3.54 ± 0.34 
 
0.35 
ALT (U/L) 21.18 ± 6.87 135.92 ± 41.86 < 0.001 
ALP (U/L) 88.78 ± 35.48 164.98 ± 47.42 < 0.001 
Pon-1 activity (nmol/ml/min) 176.68 ± 25.88 101.88 ± 23.08 < 0.001 
Table 7 - Comparison of demographic variables, standard liver function tests and basal PON-
1 activity in chronic hepatitis cases and healthy controls. 
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and negative predictive value of 75%. However, although PON-1 activity seems to be a 
more reliable predictor of liver disease compared to total protein, albumin and ALP levels, 
when bilirubin and ALT are taken into account they still show better results in terms of 
predictability of disease than basal PON-1 activity. The analysis of the receiver operating 
characteristic (ROC) curve (figure 13)  demonstrated that, among the study parameters, 
ALT demonstrated highest diagnostic accuracy (AUC=0.999) followed by total bilirubin 
(AUC=0.977), PON-1 (AUC=0.990), ALP (AUC=0.904), total protein (AUC=0.790) and 
albumin (AUC=0.595) (Pyati, 2015). These findings were similar to those observed in 
the study conducted by (Ferré et al. 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The measurement of PON-1 activity may represent a significant improvement in liver 
disease detection. The analysis of the data provided by the ROC curves (Ferré et al., 2002;  
Pyati, 2015) demonstrated that serum PON-1 activity is, in fact, worth exploring. The 
ROC analysis also supports that the measurement of baseline serum PON-1 activity is an 
excellent candidate to become a biomarker for liver disease. Although bilirubin and ALT 
seem to be more accurate biomarkers than PON-1, they are only indicatives of some types 
of liver injuries (Pyati, 2015). 
 The quantification of serum PON-1 activity is a simple, reliable, inexpensive and 
a) 
Fig. 13 – Diagnostic accuracy of serum biomarkers in the diagnosis of chronic hepatitis. a) bilirubin 
(BLUE), ALT (GREEN), ALP (YELLOW); b) total protein (BLUE), Albumin (GREEN) and PON-1 
(YELLOW) ; reference line  (PURPLE). Adapted from  Pyati, (2015)    
 
Specificity 
Specificity 
ROC CURVES 
Sensitivity Sensitivity 
b) 
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easily automated method that can be performed in most automated analyzers used for 
standard biochemical liver function tests. A disadvantage of the assay is the elevated 
toxicity of paraoxon (in the cases were paraoxonase activity is in analisys) (Ferré, Camps, 
Cabré, Paul & Joven, 2001; Ferré et al. 2002; Pan, Ma, Bo & Guo, 2011; Pyati, 2015).  
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2.2.2 – PON-1 ACTIVITY AND OXIDATIVE STRESS IN THE LIVER 
 
Hepatocytes are constantly exposed to reactive oxygen species (ROS), but protected 
from oxidative injury by a range of antioxidant pathways. The defenses against free 
radical-mediated injury include enzymatic deactivation and direct reaction with free 
radicals (Osman, Gabr, Lotfy, & Gabr 2007).  
Although free radicals are normally produced by many reactions essential for cell 
metabolism and energy production, they are implicated also in the pathogenesis of several 
different human diseases, including viral infections such as HBV or HBC (Schwarz, 
1996).  
In patients with viral or alcoholic liver disease, the consequent alternation of cellular 
redox state is potentiated by a decrease in the antioxidant enzymes and an increase of free 
radical-mediated damage and apoptosis of liver cells (Loguercio & Federico, 2003).  
Several studies suggested that free radical generation and oxidative stress play an 
important role in the mechanisms developed by HCV to survive and progress in the 
infected host (Cardin et al., 2001; Thorén, Romero, Lindh, Dahlgren & Hellstrand, 2004; 
Waris, Turkson, Hassanein & Siddiqui, 2005).  
Lipid peroxidation is caused by free radicals leading to oxidative destruction of 
polyunsaturated fatty acids constitutive of cellular membranes. The destruction of 
polyunsaturated fatty acids leads to the production of toxic and reactive aldehyde 
metabolites such as malonaldehyde (MDA) (Levent et al., 2006). MDA content usually 
reflects the level of lipid peroxidation and indirectly reflects the extent of hepatocellular 
injury in vivo (Osman et al., 2007).  
In the study by Ali et al. (2009), it was established that serum MDA levels were higher 
in patients with HCV than the healthy ones. This result considers the consequence of lipid 
peroxidation in the pathophysiology of patients with HCV. Serum MDA concentration in 
patients with chronic active hepatitis C as well as transaminase and bilirubin levels were 
found to be increased in many other studies (Mansurova, Mutikhova, & Olimova, 2005; 
Levent et al., 2006; Osman et al., 2007). MDA was showed to be elevated in the liver and 
the blood of patients with HCV as reported by De Maria et al. (1996). Moreover, Boya et 
al. (1999) reported that, the peripheral blood mononuclear cells separated from chronic 
hepatitis C patient had increased MDA concentrations.  
According to Boya et al. (1999), serum arylesterase (AE) and PON-1 activities have 
decreased in the chronic and cirrhotic hepatitis C patients compared to the control group
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  Some recent studies are in agreement with the present investigation such as 
Gangadharan, Antrobus, Dwek, & Zitzmann, (2007) who found a decreasing in serum 
AE and PON-1 activities in chronic and cirrhotic HCV patients compared with healthy 
controls. The study proposed that serum AE and PON-1 carried in circulation bounded to 
HDL particles protect LDL from peroxidation, supported by  Mackness, Durrington, & 
Mackness, (2004). Thus, there are two possible explanations for decreased PON-1 and 
AE activities in chronic hepatitis. Firstly, the decrease in PON-1 and AE enzymatic 
activities or gene expression could be the consequence of the hepatic dysfunction. The 
second is that serum PON and AE activities could be decreased as a consequence of an 
altered synthesis and/or secretion of HDL (Ali et al., 2009).  
PON-1 and AE act as antioxidants that protect LDL from oxidative modifications and 
can reduce oxidized lipid in oxidized lipoproteins (Mackness et al., 2004; Kilic, Aydin, 
Kilic, Erman, Aydin, & Celik, 2005). Other important observation in the study by Ali et 
al., (2009)  was that the activities of both enzymes have significantly decreased in 
cirrhotic more than in chronic HCV patients, indicating that the level of decrease in AE 
and PON-1 activity in the serum of patients with chronic liver diseases is probably a 
consequence of liver dysfunction. That could emphasize the prognostic value of AE and 
PON-1 in HCV infected patients and give clinicians a signal for deterioration of the liver 
function with the progression of the disease. The results also demonstrated that serum AE 
was negatively correlated with serum ALT and aspartate aminotransferase (AST) 
activities; whereas serum PON-1 was negatively correlated with serum ALT, AST and 
ALP activities and serum total bilirubin and direct bilirubin levels in HCV patients group. 
Kilic, Aydin, Kilic, Erman, Aydin, & Celik, (2005) are in agreement with Ali et al., (2009) 
that serum AE and PON-1 activities were also negative correlated with serum ALT and 
AST activities and albumin and bilirubin concentrations as well as between serum PON-
1 and ALP activity. 
Ali et al. (2009) states that a negative significant correlation was found between PON-
1 and MDA in HCV patients. Ferré et al. (2006) reported that, increased serum PON-1 
concentrations and raised hepatic PON-1 expression were associated with higher 
peroxidation in serum and liver biopsies. On the other hand, Başkol et al., (2005) found  
no statistically significant correlations between hepatic PON-1 activity and serum lipid 
levels or serum MDA levels in patients with non-alcoholic steatohepatitis. Moreover, 
PON-1 has been found to influence the anti-apoptotic ability of the HDL molecule, 
because it has the capacity to protect the lipoprotein against oxidation. 
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PON-1 has an active role in the regulation of oxidative stress, fibrosis and hepatic cell 
apoptosis in chronic liver diseases (Ferré et al., 2006). Marsillach et al. (2007) reported 
that, PON-1 activity measurement would be very useful in discriminating between 
alcoholic patients and healthy subjects.  
When studying the ROC curves of both AE and PON-1, it was found that the areas 
under the curves were 0.968 and 0.966 respectively, and best cutoff values of serum AE 
and PON-1 were 764 and 482 nmol/min/ml respectively. Applying these cutoff values, 
the maximum sensitivity, specificity, positive predictive and negative predictive values 
of (AE and PON-1) were (86% and 79.5%), (90% and 100%), (95% and 100%) and (76% 
and 70%) respectively (Ali et al., 2009).  
The study by  Marsillach et al., (2007) reported that, PON-1 activity measurement 
would be very useful in discriminating between alcoholic patients and healthy subjects; 
on studying the ROC curve of PON-1 activity, the area under the curve of PON-1 activity 
was ≥0.90, the increased sensitivity up to 83.5–96.6% and specificity up to 95.8–99.6%. 
AE was the hepatitis C biomarker marker which showed the highest sensitivity, when 
measured as a single marker without any combination with others, while MDA or PON-
1 was the marker which gave the highest specificity, when each of them was measured 
alone without combination. But in combination, the best combined ones for sensitivity, 
specificity, positive predictive value (PPV) and negative predictive value (NPV) were 
MDA plus albumin, PON-1 plus albumin and PON-1 plus AST (Marsillach et al., 2007).  
The over release of the oxidative free radicals [MDA, nitric oxide (NO) and 
myeloperoxidase (MPO)] and the decrement of the antioxidants (PON-1 and AE) might 
play a role in the pathogenesis of viral hepatitis. Moreover, these markers are beneficial 
in testing liver dysfunction and detecting high-risk patients of cirrhotic from chronic HCV 
liver disease patients (Ali et al., 2009; Pyati, 2015). 
 Both PON-1 and AE could be considered as prognostic biomarkers of oxidative stress 
in HCV infection. If any abnormality of their levels is detected in chronic patients that 
could be a warning sign for occurrence of cirrhosis. Even more, changes in the levels of 
these markers in a normal person can give a risk sign to detect any early liver dysfunction. 
Therefore, these markers could produce a diagnostic and prognostic index which may 
improve sensitivity and specificity when combined with the other conventional liver 
function markers. Moreover, inclusion of antioxidants as adjunct in the management of 
chronic and cirrhotic HCV patients should be planned to prevent progressive deterioration 
and target liver damage (Ali et al., 2009).
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2.2.3 – PON-1 ACTIVITY AND HBV INFECTIONS 
 
Karsen et al. (2012) proposed that, serum PON-1 concentration was considerably 
lower in patients with chronic hepatitis B than in the control group. The results presented 
that patients with chronic hepatitis B are exposed to oxidative stress and showed 
decreased PON-1 activity. The study proposes that predisposal factors may also, in part, 
play a role in the pathogenesis of atherosclerosis in patients with chronic hepatitis B.  
There is a well-established relation between the enzyme PON-1 in cardiovascular 
diseases and atherosclerosis (Michael I Mackness et al., 2004; Yilmaz, 2012; Kim, 
Marsillach, Furlong, & Jarvik, 2013; Kulka, 2016). (Draganov & La Du, 2004). HDL 
PON-1 activity is shown to be associated with modulation of endothelial functions and 
regulation of coronary vasomotor tone. (Malin et al., 2001; Pasqualini et al., 2005) 
Increased incidence of subclinical atherosclerosis in carotid arteries has been reported in 
patients with chronic hepatitis B (Alkhouri et al., 2010). On the other hand, other studies 
have been unable to demonstrate any difference between chronic hepatitis B and controls 
and indicated that HBs Ag seropositivity was not related with increased mortality risks of 
atherosclerosis related cardiovascular diseases (Wang, Chen, Lee, Yang & Hsiao, 2010). 
The reduction of PON-1 activity under oxidative stress is an independent risk factor 
for coronary arterial disease and mostly attributed to changes in the redox status of the 
free sulfhydryl groups of proteins since sulfhydryl prevent the inhibition of PON-1 
activity (Mackness et al., 2001). Free sulfhydryl groups of proteins constitute the main 
antioxidant component of serum and have been shown to be associated with the coronary 
heart disease (Rozenberg & Aviram, 2006).  
Free radicals are produced in metabolic and physiological processes, and harmful 
oxidative reactions may occur in organisms. Organisms are protected against oxidative 
stress via enzymatic and non-enzymatic antioxidative mechanisms. Under normal 
conditions, a balance exists between free radical formation and their removal by 
antioxidant enzymes and other molecules (Mackness et al., 2001).  
Karsen et al. (2012)  also develops the claim that to measure impact of oxidative 
stress, the total antioxidant and oxidant parameters should be taken into consideration 
instead of individual compounds such as superoxide dismutase, catalase, glutathione 
peroxidase, and glutathione reductase. This approach is supported by the fact of 
antioxidants act in combination with each other affecting total capacity and producing 
synergistic or antagonistic effects. Also, according to Karsen et al. (2012), free sulfhydryl 
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groups in plasma, and total antioxidant capacity levels were significantly lower in chronic 
hepatitis B subjects than observed in the control group, while LOOH, total oxidant status 
levels and oxidative stress index were significantly higher. These results represent the 
severe oxidative stress in patients with chronic hepatitis B infection. On one hand, chronic 
hepatitis B is the most common cause of hepatocellular carcinoma but on the other hand 
it could contribute to the development of atherosclerosis (Karsen et al., 2012). 
In light of the results of the study by Karsen et al. (2012)  it is possible to determine 
that oxidative stress is increased, while serum PON-1 is decreased, in chronic hepatitis B 
patients. The decrease in paraoxonase activity could contribute to the accelerated 
development of atherosclerosis in patients with chronic hepatitis B. This same 
conclusions  are also stated by other authors (Farid & Horii, 2012) 
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CONCLUSIONS 
 
Several studies conclude that significant alterations occur on the enzymatic activity 
of PON-1 in HIV, HBV and HCB infected patients. This modifications seem to occur due 
to the increased levels caused by the infections on the organism, leading to multiple 
disruption on antioxidant and anti-inflammatory pathways that seem were demonstrated 
to involve PON-1. 
Although PON-1 activity alterations seem to be caused by malignant causes, positive 
and useful clinical information might be extracted by measuring such alterations. PON-1 
possibly will be used with more research in future as a biomarker.  
In HIV infections, there are well established markers for evaluating the infection 
status, however the insight provided by the additional  monitoring of PON-1 activity 
could, in fact, be extremely useful. This additional assessment might lead to the 
prevention of the most common complications due to the chronic use of ART, such as 
cardiovascular disease and dyslipidemias. This prevention can be achieved by obtaining 
a more suitable diagnostic tool, for the disease progression and all its complications and 
by doing so, applying preventive measures that could avoid such complications (Coll et 
al., 2006; Parra et al., 2007; Pereira et al., 2009; Dias et al., 2014). 
In regards to clarifying whether PON-1 could be used as a biomarker for HBV or 
HCV infections, several works including those of Ali et al., (2009), Pyati, (2015)  
Marsillach et al., (2007) demonstrated that the precision of PON-1 as a marker for disease 
is similar to those of ALT or bilirubin, already well accepted and used parameters of 
analysis (Pyati, 2015).  
The enzyme PON-1, in addition to its possible biomarker applications in both HIV, 
HBV and HCV infections, revealed an extremely important role in the oxidative stress 
caused by those infections. As an enzyme with anti-oxidant proprieties and closely 
involved in regulating LDL peroxidation, in both cases the activity of the enzyme was 
closely associated with the progression of the disease which can definitely provide useful 
analytic  tools for the diagnose and evaluation of those patients (Ferré et al., 2006; 
Mackness, Arrol, Abbott, & Durrington, 1993; Valyi-Nagy & Dermody, 2005). 
More studies in this area are needed in order to better access whether PON-1 is worth 
to be taken into account or should be disregarded. However, the ground work done so far 
presents very positive outcomes for the future. 
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